Anbieter: Books From California, Simi Valley, CA, USA
paperback. Zustand: Fine.
Anbieter: Books From California, Simi Valley, CA, USA
paperback. Zustand: Very Good. Cover and edges may have some wear.
Zustand: New.
Anbieter: PBShop.store US, Wood Dale, IL, USA
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Zustand: As New. Unread book in perfect condition.
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
EUR 25,09
Anzahl: 2 verfügbar
In den WarenkorbPAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Sprache: Englisch
Verlag: National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Anbieter: Grand Eagle Retail, Bensenville, IL, USA
Paperback. Zustand: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Anbieter: Chiron Media, Wallingford, Vereinigtes Königreich
EUR 21,77
Anzahl: 2 verfügbar
In den Warenkorbpaperback. Zustand: New.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 24,71
Anzahl: 3 verfügbar
In den WarenkorbZustand: New.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 26,71
Anzahl: 2 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 27,17
Anzahl: 3 verfügbar
In den WarenkorbZustand: As New. Unread book in perfect condition.
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
EUR 28,27
Anzahl: 2 verfügbar
In den WarenkorbPaperback / softback. Zustand: New. New copy - Usually dispatched within 3 working days.
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. 2025. paperback. . . . . .
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. 2025. paperback. . . . . . Books ship from the US and Ireland.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 45,77
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.
Sprache: Englisch
Verlag: National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Anbieter: CitiRetail, Stevenage, Vereinigtes Königreich
EUR 28,90
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Sprache: Englisch
Verlag: National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Anbieter: AussieBookSeller, Truganina, VIC, Australien
Paperback. Zustand: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
Sprache: Englisch
Verlag: National Academies Press Sep 2025, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Neuware - The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.